IL284636A - Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefore - Google Patents
Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses thereforeInfo
- Publication number
- IL284636A IL284636A IL284636A IL28463621A IL284636A IL 284636 A IL284636 A IL 284636A IL 284636 A IL284636 A IL 284636A IL 28463621 A IL28463621 A IL 28463621A IL 284636 A IL284636 A IL 284636A
- Authority
- IL
- Israel
- Prior art keywords
- preparation
- methods
- solid dispersion
- raf kinase
- stable solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019073254 | 2019-01-25 | ||
| CN2019095227 | 2019-07-09 | ||
| PCT/CN2020/073944 WO2020151756A1 (en) | 2019-01-25 | 2020-01-23 | Stable solid dispersions of b-raf kinase dimer inhibitor, methods of preparation, and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284636A true IL284636A (en) | 2021-08-31 |
Family
ID=71735582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284636A IL284636A (en) | 2019-01-25 | 2021-07-06 | Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefore |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12582604B2 (enExample) |
| EP (1) | EP3914591A4 (enExample) |
| JP (2) | JP7591504B2 (enExample) |
| KR (1) | KR20210120039A (enExample) |
| CN (1) | CN113330011A (enExample) |
| AU (1) | AU2020211000B2 (enExample) |
| BR (1) | BR112021014563A2 (enExample) |
| CA (1) | CA3123476A1 (enExample) |
| IL (1) | IL284636A (enExample) |
| MX (1) | MX2021008884A (enExample) |
| SG (1) | SG11202107849RA (enExample) |
| TW (2) | TWI849043B (enExample) |
| WO (1) | WO2020151756A1 (enExample) |
| ZA (1) | ZA202104032B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111484490B (zh) * | 2019-01-25 | 2024-07-09 | 百济神州有限公司 | 适合大规模生产b-raf激酶二聚体抑制剂的方法 |
| TWI849043B (zh) | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| AU2021412688B2 (en) * | 2020-12-29 | 2025-06-12 | Txinno Bioscience Inc. | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| KR102889693B1 (ko) | 2021-09-08 | 2025-11-20 | 주식회사 엘지에너지솔루션 | 배터리 진단 장치, 배터리 관리 시스템, 배터리 팩, 전기 차량 및 배터리 진단 방법 |
| CN114366717B (zh) * | 2022-01-11 | 2023-06-09 | 四川农业大学 | 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用 |
| JP2025519981A (ja) * | 2022-06-08 | 2025-06-30 | マップキュア,エルエルシー | B-raf阻害剤によるがんの治療方法 |
| JP2025532826A (ja) * | 2022-09-26 | 2025-10-03 | マップキュア,エルエルシー | がんの処置のためのb-raf阻害剤と、抗egfr抗体との組み合わせ |
| JP2026507361A (ja) * | 2023-03-10 | 2026-03-02 | エスティー ファーム カンパニー リミテッド | 新規固体分散体およびその製造方法 |
| TW202515875A (zh) | 2023-10-12 | 2025-04-16 | 瑞士商百濟神州瑞士有限責任公司 | 包含b-raf激酶二聚體抑制劑之固體形式、其製備方法及用途 |
| WO2025252204A1 (en) * | 2024-06-07 | 2025-12-11 | Beigene (Suzhou) Co., Ltd. | Amorphous solid dispersions of a braf inhibitor |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| EP1027885B1 (en) | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Basic drug compositions with enhanced bioavailability |
| SE0100733D0 (sv) | 2001-03-05 | 2001-03-05 | Medivir Ab | Non-nucleoside reverse transcriptase inhibitors |
| KR20050033663A (ko) | 2002-09-05 | 2005-04-12 | 메디비르 아베 | 비-뉴클레오시드 역전사효소 억제제 |
| JP5138938B2 (ja) | 2003-12-19 | 2013-02-06 | プレキシコン インコーポレーテッド | Ret調節剤の開発のための化合物および方法 |
| EP1833829A2 (en) | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| WO2007067444A1 (en) | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| AU2007254325B2 (en) | 2006-05-15 | 2012-05-10 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| BRPI0716477A2 (pt) | 2006-09-06 | 2014-03-18 | Hoffmann La Roche | Derivados heteroarila como inibidores de quinase protéica |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| JP2010526848A (ja) | 2007-05-11 | 2010-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | 難溶性薬物用の医薬組成物 |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| AU2009226136B2 (en) * | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| US20100197924A1 (en) | 2008-12-22 | 2010-08-05 | Millennium Pharmaceuticals, Inc. | Preparation of aminotetralin compounds |
| CA2738573C (en) * | 2009-04-03 | 2013-02-19 | F. Hoffmann-La Roche Ag | Compositions of propane-1 sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and uses thereof |
| SG178854A1 (en) * | 2009-08-28 | 2012-04-27 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
| AU2011209234B2 (en) | 2010-01-27 | 2015-05-07 | Nerviano Medical Sciences S.R.L. | Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors |
| WO2011115069A1 (ja) | 2010-03-19 | 2011-09-22 | 第一三共株式会社 | 結晶の網羅的探索 |
| PE20141360A1 (es) * | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
| DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| IN2015DN00450A (enExample) * | 2012-08-07 | 2015-06-26 | Novartis Ag | |
| NZ708272A (en) | 2013-01-22 | 2020-07-31 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| JP2014189462A (ja) | 2013-03-27 | 2014-10-06 | Osaka Univ | 結晶製造方法、準安定形結晶、医薬の製造方法および医薬 |
| WO2014206344A1 (en) * | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| WO2014206343A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
| WO2015152433A1 (en) * | 2014-03-31 | 2015-10-08 | Hanmi Pharm. Co., Ltd. | Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same |
| TWI849043B (zh) | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
-
2020
- 2020-01-22 TW TW109102401A patent/TWI849043B/zh active
- 2020-01-22 TW TW113123511A patent/TWI909513B/zh active
- 2020-01-23 WO PCT/CN2020/073944 patent/WO2020151756A1/en not_active Ceased
- 2020-01-23 KR KR1020217026908A patent/KR20210120039A/ko active Pending
- 2020-01-23 CA CA3123476A patent/CA3123476A1/en active Pending
- 2020-01-23 BR BR112021014563-0A patent/BR112021014563A2/pt unknown
- 2020-01-23 MX MX2021008884A patent/MX2021008884A/es unknown
- 2020-01-23 AU AU2020211000A patent/AU2020211000B2/en active Active
- 2020-01-23 EP EP20744694.9A patent/EP3914591A4/en active Pending
- 2020-01-23 US US17/423,600 patent/US12582604B2/en active Active
- 2020-01-23 CN CN202080010548.8A patent/CN113330011A/zh active Pending
- 2020-01-23 JP JP2021542104A patent/JP7591504B2/ja active Active
- 2020-01-23 SG SG11202107849RA patent/SG11202107849RA/en unknown
-
2021
- 2021-06-11 ZA ZA2021/04032A patent/ZA202104032B/en unknown
- 2021-07-06 IL IL284636A patent/IL284636A/en unknown
-
2024
- 2024-11-18 JP JP2024200421A patent/JP2025017374A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3914591A1 (en) | 2021-12-01 |
| AU2020211000A1 (en) | 2021-08-12 |
| TW202444718A (zh) | 2024-11-16 |
| AU2020211000B2 (en) | 2025-11-06 |
| JP2025017374A (ja) | 2025-02-05 |
| CA3123476A1 (en) | 2020-07-30 |
| US20220105033A1 (en) | 2022-04-07 |
| KR20210120039A (ko) | 2021-10-06 |
| TW202043225A (zh) | 2020-12-01 |
| WO2020151756A1 (en) | 2020-07-30 |
| CN113330011A (zh) | 2021-08-31 |
| EP3914591A4 (en) | 2022-11-09 |
| SG11202107849RA (en) | 2021-08-30 |
| TWI849043B (zh) | 2024-07-21 |
| ZA202104032B (en) | 2022-08-31 |
| TWI909513B (zh) | 2025-12-21 |
| JP2022517675A (ja) | 2022-03-09 |
| BR112021014563A2 (pt) | 2021-10-05 |
| JP7591504B2 (ja) | 2024-11-28 |
| MX2021008884A (es) | 2021-08-19 |
| US12582604B2 (en) | 2026-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202104032B (en) | Stable solid dispersion of a b-raf kinase dimer inhibitor, methods of preparation, and uses therefore | |
| IL250447A0 (en) | Stable and soluble formulations of receptor tyrosine kinase inhibitors and methods for their preparation | |
| EP3399968B8 (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase | |
| EP3868762A4 (en) | Mst1 kinase inhibitor and use thereof | |
| IL283599A (en) | Tyrosine kinase inhibitors, preparations and methods | |
| EP3648753A4 (en) | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF EGFR TYROSINE KINASE | |
| EP3250192A4 (en) | Compositions and methods of using tyrosine kinase inhibitors | |
| IL315294A (en) | Pharmaceutical formulations of proton tyrosine kinase inhibitor | |
| EP3293177A4 (en) | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | |
| MX2018007421A (es) | Compuestos inhibidores de quinasa de union a tank. | |
| IL255555B (en) | Maleate salts of b-raf kinase inhibitors, crystalline forms, methods for their preparation and uses | |
| DK3429591T3 (da) | Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse | |
| EP3310339A4 (en) | OPHTHALMIC FORMULATIONS OF TYROSINE KINASE INHIBITORS, METHOD OF USE THEREOF AND METHOD OF PRODUCTION THEREOF | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| DK3691620T3 (da) | P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| UY35798A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
| MX374558B (es) | Compuestos de heteroarilo y sus usos. | |
| EP3347462A4 (en) | METHOD, COMPOSITIONS AND USE OF NOVEL FYN KINASEINHIBITORS | |
| EP3543239C0 (en) | SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE | |
| HUE066253T2 (hu) | Benzoazepin analógok a bruton tirozin kináz gátlószereként | |
| WO2011106248A3 (en) | Trimethoxyphenyl inhibitors of tyrosine kinase | |
| EP3448852A4 (en) | NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL | |
| PL3704118T3 (pl) | Aminotriazolopirydazyny jako inhibitory kinaz | |
| EP3328496A4 (en) | Inhibitors of ack1/tnk2 tyrosine kinase |